Related Experiment Video
Updated: Feb 6, 2026

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
Ticagrelor versus clopidogrel for recovery of vascular function immediately after successful chronic coronary total
Salvatore Brugaletta1, Josep Gomez-Lara2, Juan Caballero3
1Cardiovascular Institute, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Insights
Ticagrelor may improve coronary blood flow after chronic total occlusion (CTO) percutaneous coronary intervention (PCI). This study compared ticagrelor
Area of Science:
- Cardiovascular Medicine
- Interventional Cardiology
- Pharmacology
Background:
- Chronic total occlusions (CTOs) often exhibit impaired coronary vascular function post-recanalization.
- Percutaneous coronary intervention (PCI) aims to restore blood flow but immediate functional recovery can be limited.
- Adenosine is used to assess coronary blood flow, a key indicator of vascular health.
Discussion:
- This research investigates the potential of ticagrelor to enhance adenosine-induced coronary blood flow compared to clopidogrel.
- The study focuses on the immediate post-successful CTO PCI period.
- Evaluating P2Y12 inhibitors' impact on microvascular function after CTO recanalization is crucial.
Key Insights:
- Ticagrelor demonstrated a potential to augment coronary blood flow post-CTO PCI.
- The study provides immediate functional data comparing ticagrelor and clopidogrel.
- Findings suggest a possible role for ticagrelor in improving early vascular recovery.
Outlook:
- Further research could explore long-term functional outcomes and clinical benefits.
- Investigating optimal antiplatelet strategies post-CTO PCI is warranted.
- Exploring the mechanisms behind ticagrelor's effect on coronary microvasculature is a future direction.
Abstract:
Coronary vascular function of a chronic coronary total occlusion (CTO) immediately after recanalization is known to be poor. We sought if ticagrelor may augment adenosine-induced coronary blood flow vs. clopidogrel immediately after successful CTO percutaneous coronary intervention (PCI).
More Related Videos
04:44Author Spotlight: Enhancing Vascular Function and Physical Capacity in Cardiovascular Disease Through Novel Interventions and NIRS Technology
Published on: March 22, 2024
10:28Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
Related Concept Videos
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Statistical Software for Data Analysis and Clinical Trials
Ecological Succession
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
Coronary Artery Disease III: Clinical Manifestations